Boehringer Ingelheim to Present Latest Data from Robust Respirator?y Portfolio

Boehringer Ingelheim has announced the upcoming presentation of data from 11 abstracts, including six oral presentations, across the company's respiratory portfolio at the 2013 American College of Chest Physicians (ACCP) annual meeting, CHEST 2013, taking place 26–31 October in Chicago. These data exemplify Boehringer Ingelheim's continued commitment to lung health and to discovering new therapies for patients and physicians where unmet needs exist.

These data will highlight ongoing research from the company's development programmes for asthma and chronic obstructive pulmonary disease (COPD), and provide additional information on the once-daily COPD maintenance therapy, Spiriva HandiHaler (tiotropium bromide inhalation powder). Data from the TIOSPIR (Tiotropium Safety and Performance in Respimat) trial, one of the largest international COPD trials conducted to date, will also be presented.

Tiotropium in Asthma

The CHEST programme includes a session titled "Tiotropium and Asthma", which will feature four oral presentations from from the tiotropium development programme for adults with severe persistent asthma, including one Phase II study and analyses from the PrimoTinA-asthma Phase III trials. The presentations focus on new analyses and data, including expanded analyses of safety and exacerbation data. The PrimoTinA-asthma studies are designed to evaluate once-daily tiotropium delivered via the Respimat inhaler as add-on therapy to inhaled corticosteroid/long-acting beta agonists (ICS/LABA) in symptomatic patients with severe persistent asthma. Tiotropium delivered via the Respimat inhaler is being investigated to determine its efficacy and safety in treating patients with asthma and is not approved for this indication.